A Chinese mRNA COVID vaccine gets its first approval | By The Perfect Enemy

JAKARTA/BEIJING, Sept 30 (Reuters) – Indonesia said it has granted emergency use approval to an mRNA COVID-19 vaccine developed by a Chinese company, becoming the first country, ahead of even China, to do so.

Indonesia’s food and drugs agency (BPOM) greenlighted the use of Walvax Biotechnology’s (300142.SZ) mRNA vaccine, which has been in development for more than two years and targets the original strain of the coronavirus.

The approval comes as a surprise as Walvax, which has been conducting large late-stage trials of the vaccine in several countries including Indonesia, Mexico and China, has yet to publish efficacy readings that would show how well it can reduce the risk of COVID cases and deaths.

Register now for FREE unlimited access to Reuters.com

Penny Lukito, head of the agency, told reporters the vaccine, now known as AWcorna, was 71.17% effective against the highly contagious Omicron variant and 83.58% against wild-type coronavirus strains considered common and normal. She did not provide details.

Walvax did not immediately reply to a Reuters request for comment.

China has several mRNA candidates in development but the Walvax vaccine is the only candidate in large late-stage clinical trials.

It was not immediately clear how widely the newly approved shot will be used in Indonesia, where more than 63% of its population is fully vaccinated. Health experts around the world also recommend using so-called bivalent COVID vaccines, which target both the original strain and the Omicron variant.

Indonesia also uses mRNA COVID vaccines made by Pfizer -BioNTech (22UAy.DE) and Moderna (MRNA.O), but the AWcorna shot has a longer shelf life, remaining stable at 2-8 degrees Celsius for at least six months, according to its researchers. read more

That could make the vaccine ideal for countries with poor logistics in remote areas. Indonesia is an archipelago of thousands of islands.

BPOM said the vaccine’s less stringent storage requirements suited Indonesia, a tropical country, and it could be used as both a primary and a booster shot for adults.

The vaccine will be locally produced by an Indonesian firm, Etana Biotechnologies.

Walvax co-developed the vaccine with Suzhou Abogen Biosciences and a Chinese military-backed institution.

Walvax and Suzhou Abogen are also separately working on their own mRNA candidates that target coronavirus variants.

For its part, China has not approved any Western-made COVID shots and its approved vaccine portfolio does not yet include vaccines that specifically target the Omicron variant.

Register now for FREE unlimited access to Reuters.com

Reporting by Stanley Widianto in Jakarta and Roxanne Liu in Beijing; Editing by Miyoung Kim and Edwina Gibbs

Our Standards: The Thomson Reuters Trust Principles.

#Coronavirus, #Vaccines

---

Published on The Perfect Enemy at https://bit.ly/3rlRVZu.